Showing results (151-160 of 214) with videos related to
Sort By:
Pageof 22
JAMA Oncology|January 21, 2021
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical TrialDavendra P S Sohal, Mai Duong, Syed A Ahmad, et al.Annals of Surgery|August 3, 2020
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal AdenocarcinomaSyed A Ahmad, Mai Duong, Davendra P S Sohal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2010
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium studySam J Lubner, Michelle R Mahoney, Jill L Kolesar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal AdenocarcinomaAsfar S Azmi, Husain Yar Khan, Irfana Muqbil, et al.Targeted Oncology|March 27, 2025
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid TumorsCathy Eng, Nehal J Lakhani, Philip A Philip, et al.Journal of Gastrointestinal Oncology|November 18, 2021
Molecular characterization of squamous cell carcinoma of the anal canalSamantha A Armstrong, Rita Malley, Hongkun Wang, et al.Cancers|April 3, 2020
Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor GrowthHusain Yar Khan, Gabriel B Mpilla, Rachel Sexton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2010
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancerCarol M Moinpour, Nancy L Vaught, Bryan Goldman, et al.NPJ Precision Oncology|June 15, 2026
Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligenceSebastian Cole, Paul Campitelli, Brian Grieb, et al.World Journal of Gastroenterology|March 6, 2015
Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumorsJonathan R Strosberg, George A Fisher, Al B Benson, et al.Pageof 22